Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.60 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997494 | 0.87 | CYP11B2 (0.52) | CYP11B2CYP11B1TACR3MAPTNPSR1 | |
| SCHEMBL5003151 | 0.82 | MAPT (0.50) | CYP11B2CYP11B1TACR3MAPTLMNA | |
| SCHEMBL5003086 | 0.81 | CYP11B1 (0.47) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL5000719 | 0.78 | CYP11B1 (0.47) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL4992156 | 0.78 | CYP11B1 (0.49) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL4992899 | 0.78 | CYP11B1 (0.45) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL5000472 | 0.76 | CYP11B1 (0.53) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL20460041 | 0.75 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL4997662 | 0.74 | CYP11B1 (0.46) | CYP11B2CYP11B1PIM1PIM3PIM2 | |
| SCHEMBL5000701 | 0.74 | LMNA (0.51) | CYP11B2CYP11B1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | CYP11B2 112/4885CYP11B1 132/4885TACR3 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.